

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CANbridge Pharmaceuticals Inc.

北海康成製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1228)

CLOSURE OF REGISTER OF MEMBERS

The board (the “**Board**”) of directors (the “**Director**”) of CANbridge Pharmaceuticals Inc. (the “**Company**”) hereby announces that an extraordinary general meeting (the “**EGM**”) of the Company will be held on Thursday, December 4, 2025. For the purpose of determining the identity of the Shareholders entitled to attend and vote at the EGM, the register of members of the Company will be closed from Monday, December 1, 2025, to Thursday, December 4, 2025, both days inclusive, during which period no transfer of shares will be effected. Shareholders whose names appear on the register of members of the Company on Monday, December 1, 2025, shall be entitled to attend and vote at the EGM. In order to be qualified to attend and vote at the EGM, all transfers accompanied by the relevant certificates must be lodged with the Hong Kong Share Registrar of the Company, Computershare Hong Kong Investor Services Limited at Shops 1712-1716, 17th Floor, Hopewell Centre, 183 Queen’s Road East, Wan Chai, Hong Kong for registration not later than 4:30 p.m. on Friday, November 28, 2025.

A circular containing, among other things, detailed information of the resolution(s) to be proposed at the EGM, together with the notice of EGM, will be despatched to the Shareholders on or about November 19, 2025.

Yours faithfully,
By order of the Board
CANbridge Pharmaceuticals Inc.
Dr. James Qun Xue
Chairman

Hong Kong, November 17, 2025

As of the date of this announcement, the Board comprises Dr. James Qun Xue as executive Director; Ms. Wei Zhao and Mr. Tingwei Wang as non-executive Directors; and Dr. Richard James Gregory, Mr. James Arthur Geraghty, Mr. Peng Kuan Chan and Dr. Lan Hu as independent non-executive Directors.